Can I Take Folate with Jardiance? What Every Woman Should Know

The short answer: folate and Jardiance do not interact in a clinically significant way

No published pharmacokinetic study has found that folic acid or methylfolate alters the absorption, distribution, metabolism, or excretion of empagliflozin. The reverse is also true: empagliflozin does not appear to deplete folate or interfere with folate-dependent methylation pathways based on current prescribing data.

"no interaction" is not the same as "nothing to think about." Women taking Jardiance often have type 2 diabetes, heart failure, or chronic kidney disease, and many also have PCOS, a prior neural tube defect pregnancy, or an MTHFR variant. Each of these conditions changes what "the right folate strategy" actually looks like for you specifically.

Why the interaction question still matters for women

Folate is rarely just a supplement. For women of reproductive age, it is a primary neural tube defect prevention tool. For women with PCOS or insulin resistance, elevated homocysteine linked to low folate status adds cardiovascular risk on top of the metabolic risk already present. For women in perimenopause, folate-dependent homocysteine metabolism intersects with estrogen decline and heart disease risk.

So the question "can I take folate with Jardiance?" is straightforward pharmacologically. The richer question is "what is the right folate plan for a woman on Jardiance, at my specific life stage, with my specific conditions?"

How empagliflozin works and why folate is pharmacologically separate

Empagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It blocks SGLT2 receptors in the proximal tubule of the kidney, preventing glucose reabsorption and causing about 70-90 grams of glucose to be excreted in urine daily at the 10 mg dose in adults with type 2 diabetes.

Empagliflozin's metabolic pathway

Empagliflozin is primarily metabolized by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 glucuronosyltransferases, not by the CYP450 enzyme system that accounts for most classic drug interactions. Folate is absorbed in the small intestine via proton-coupled folate transporter (PCFT) and reduced folate carrier (RFC), then converted to active 5-methyltetrahydrofolate in the liver and intestinal mucosa. These two pathways do not share enzymes, transporters, or receptor targets in any way that would create a clinically relevant interaction.

What about renal excretion?

Both folate and empagliflozin have renal handling components. Empagliflozin is excreted partly unchanged in urine. Folate filtered at the glomerulus undergoes proximal tubule reabsorption. There is no evidence they compete for the same transporters. Women with eGFR below 30 mL/min/1.73m² should not initiate empagliflozin for glycemic control (though it remains approved for heart failure at lower eGFR), and chronic kidney disease at that stage does affect folate metabolism independent of any drug interaction.

MTHFR, folate form, and why this matters more than timing

For a large proportion of women taking Jardiance, the more important folate question is not timing but form. Approximately 10-15% of the population carries the MTHFR C677T homozygous variant, which reduces the enzyme methylenetetrahydrofolate reductase activity by up to 70%, impairing conversion of folic acid to the active 5-methyltetrahydrofolate (5-MTHF).

MTHFR is more common in women with PCOS and metabolic disease

Women with PCOS have higher rates of insulin resistance, and emerging data suggest MTHFR variants are overrepresented in PCOS populations, possibly because impaired methylation amplifies hyperandrogenism signaling. If you have PCOS and are on Jardiance for its metabolic benefits, your folate supplementation strategy should specifically address MTHFR status.

Folic acid vs. Methylfolate: which form to choose

Standard over-the-counter folic acid (pteroylglutamic acid) requires conversion through MTHFR before it becomes biologically active. Women with MTHFR variants who take folic acid may accumulate unmetabolized folic acid without adequately raising active 5-MTHF levels. Methylfolate (5-MTHF), sold under names such as Metafolin or Quatrefolic, bypasses the MTHFR conversion step entirely.

WomanRx Folate Selection Framework for Women on Empagliflozin

| Your situation | Recommended folate form | Daily dose range | |---|---|---| | No MTHFR variant, not planning pregnancy | Folic acid or 5-MTHF | 400 mcg | | MTHFR C677T heterozygous, not planning pregnancy | 5-MTHF preferred | 400-800 mcg | | MTHFR C677T homozygous, any life stage | 5-MTHF only | 800 mcg-1 mg | | Planning pregnancy, no MTHFR | Folic acid or 5-MTHF | 400-800 mcg starting 1 month before conception | | Planning pregnancy, MTHFR confirmed | 5-MTHF | 1-5 mg (discuss with OB or MFM) | | Prior pregnancy with neural tube defect | 5-MTHF | 4-5 mg daily per ACOG guidance | | CKD stage 3b-4 on empagliflozin for heart failure | 5-MTHF | Individualize; monitor serum folate and homocysteine |

This framework is original to WomanRx and is intended as a starting point for your clinician conversation, not a substitution for individualized medical advice.

Folate across your reproductive life stage: where Jardiance fits in

Reproductive years (roughly ages 18-40)

The CDC recommends 400 mcg of folic acid daily for all women capable of becoming pregnant, regardless of whether pregnancy is planned, because roughly half of US pregnancies are unplanned. If you are a woman of reproductive age taking Jardiance for type 2 diabetes or PCOS-related metabolic disease, maintaining adequate folate status is not optional. It is baseline preventive care.

Women with type 2 diabetes carry a higher background risk of neural tube defects in their pregnancies, which makes folate adequacy even more pressing. One large case-control study found that pregestational diabetes increased the risk of neural tube defects by approximately 2-10 times compared to women without diabetes, independent of folate intake.

Trying to conceive (TTC)

Stop Jardiance before conception. Empagliflozin is classified as FDA Pregnancy Category risk: avoid use. Animal studies show fetal renal toxicity, and the mechanism of SGLT2 inhibition is expected to impair fetal kidney development during organogenesis. If you are actively trying to conceive, transition to a pregnancy-compatible diabetes medication with your physician before discontinuing contraception.

During the TTC window, folate supplementation at 400-800 mcg daily is actively recommended, beginning at least one month before conception to build adequate red blood cell folate stores. This is a period when you should be off Jardiance and on folate, so the interaction question resolves itself.

Perimenopause (roughly ages 40-55, variable)

As estrogen declines during perimenopause, cardiovascular risk increases. Estrogen normally supports endothelial function and has favorable effects on homocysteine metabolism. With estrogen falling, plasma homocysteine tends to rise in perimenopausal women, which may increase the benefit of maintaining adequate folate and B12 status.

If you are perimenopausal, have type 2 diabetes or heart failure, and are taking Jardiance, your folate strategy should factor in this homocysteine-cardiovascular connection. A serum homocysteine check, combined with red blood cell folate and B12 levels, gives a fuller picture than folate alone.

Post-menopause

Post-menopausal women are major users of Jardiance, particularly for heart failure and CKD indications. The EMPEROR-Reduced trial enrolled women (though they made up only about 24% of participants, a persistent evidence gap) and found significant reductions in the composite of cardiovascular death or heart failure hospitalization with empagliflozin 10 mg daily. Folate remains relevant in this group for cardiovascular and cognitive health, though neural tube defect prevention is no longer the primary concern.

Pregnancy and lactation: what women taking Jardiance must know

This section is required reading if there is any possibility you could become pregnant.

Pregnancy

Empagliflozin is contraindicated in the second and third trimesters of pregnancy. The FDA prescribing information states that based on animal data showing adverse renal effects when SGLT2 inhibitors were administered during the period of nephrogenesis (which corresponds to the second and third trimester in humans), empagliflozin should be discontinued as soon as pregnancy is detected if first-trimester exposure has occurred.

There are no adequate and well-controlled studies in pregnant women. The available human data consist of small case series and pharmacovigilance reports, insufficient to establish a drug-associated risk of major birth defects or miscarriage.

If you discover you are pregnant while on Jardiance: Contact your prescribing physician the same day. Switch to insulin or a pregnancy-approved diabetes medication immediately. Do not wait for your next scheduled appointment.

Folate, by contrast, is actively recommended in pregnancy. The standard is 400-800 mcg daily for low-risk women, escalating to 4-5 mg daily for women with a prior neural tube defect-affected pregnancy per ACOG Practice Bulletin 187.

Lactation

Empagliflozin is not recommended during breastfeeding. Animal studies show empagliflozin is present in rat milk at concentrations higher than maternal plasma, and rat pups exposed during lactation showed adverse renal effects including tubular dilatation. Human lactation transfer data are absent. Given the potential for serious adverse effects in the nursing infant and the lack of human data, most clinicians advise stopping empagliflozin while breastfeeding and selecting an alternative for diabetes management.

Folate supplementation during lactation is appropriate and recommended. Lactating women need 500 mcg of dietary folate equivalents daily to meet their needs and support breast milk folate content.

Contraception requirement

Because Jardiance carries fetal risk and because type 2 diabetes itself increases the risk of pregnancy complications, women of reproductive potential taking Jardiance should use reliable contraception unless actively planning and preparing for pregnancy (with medical transition off Jardiance). Discuss the safest contraception option for your full clinical picture with your prescriber, since some hormonal contraceptives can affect insulin sensitivity and glucose control.

Women-specific conditions where folate strategy intersects with Jardiance use

PCOS

Empagliflozin is used off-label in PCOS for its insulin-sensitizing and weight-reducing effects, though metformin remains the first-line off-label agent per ASRM guidelines. Women with PCOS often have elevated homocysteine, impaired folate metabolism linked to MTHFR variants, and are frequently of reproductive age with contraceptive and fertility considerations. This population benefits most from MTHFR testing and targeted methylfolate supplementation alongside any SGLT2 inhibitor use.

Type 2 diabetes and metabolic disease

Hyperglycemia impairs one-carbon metabolism, which depends on folate and B12 as cofactors. Women with poorly controlled type 2 diabetes may have suboptimal folate status even with adequate dietary intake. Empagliflozin's glucose-lowering effect may indirectly support one-carbon metabolism by reducing glucose-mediated oxidative stress, though this has not been directly studied in clinical trials.

Heart failure and CKD

For women with heart failure or CKD taking Jardiance, renal folate handling can be disrupted as eGFR falls. At eGFR below 45 mL/min/1.73m², folate and homocysteine levels should be monitored periodically, and B12 status checked concurrently. The EMPA-KIDNEY trial, which enrolled participants with CKD across a broad eGFR range, did not examine folate status as an outcome but demonstrated empagliflozin's renal protective effects extending to lower eGFR thresholds than previously studied.

Practical dosing and timing guidance

Since there is no pharmacokinetic interaction between folate and empagliflozin, you do not need to separate them by time. Taking both with breakfast is fine.

Empagliflozin standard dosing

• Type 2 diabetes: 10 mg once daily in the morning, with or without food. May increase to 25 mg once daily based on glycemic response and tolerability per FDA labeling.
• Heart failure (reduced or preserved ejection fraction): 10 mg once daily.
• CKD: 10 mg once daily.

Folate dosing by clinical situation

Taking folate with food reduces the mild nausea some women notice with higher doses (1 mg and above). Methylfolate supplements are available in 400 mcg, 800 mcg, 1 mg, and 5 mg capsules. The 5 mg prescription form (Deplin) requires a prescription in the US and is typically reserved for high-risk pregnancy or documented severe MTHFR-related folate deficiency.

Evidence gaps: what we do not know yet

Women have been chronically under-enrolled in cardiovascular and metabolic trials. In the EMPA-REG OUTCOME trial, the landmark study showing that empagliflozin reduced cardiovascular death by 38% in adults with type 2 diabetes and established cardiovascular disease, women made up only about 29% of participants. Sex-stratified data on folate metabolism, MTHFR variant frequency, or homocysteine changes during SGLT2 inhibitor therapy have not been published.

As WomanRx reviewer Dr. Maya Okafor, MD, states: "The interaction database shows no flag between folate and empagliflozin, but that is almost certainly because no one has studied folate metabolism specifically in women on SGLT2 inhibitors with MTHFR variants. The absence of data is not the same as absence of concern. Until we have that data, I counsel my patients on Jardiance to optimize folate form based on their MTHFR status, not just reach for the cheapest folic acid tablet."

This reflects a broader pattern: the drug-supplement interaction databases that clinicians and pharmacists rely on are built primarily from male-default trial data and may not capture sex-specific metabolic differences.

Who this is right for and who needs a different conversation

Jardiance plus folate is likely straightforward if you:

• Are post-menopausal taking Jardiance for heart failure or CKD
• Are a reproductive-age woman with type 2 diabetes or PCOS using reliable contraception
• Have no MTHFR variant and are taking standard-dose folic acid
• Have normal renal function (eGFR above 60 mL/min/1.73m²)

Ask your prescriber for a more detailed plan if you:

• Are planning to conceive within the next 6-12 months (transition off Jardiance first)
• Have a confirmed MTHFR C677T homozygous variant
• Had a prior pregnancy affected by a neural tube defect
• Have CKD with eGFR below 45 mL/min/1.73m²
• Are perimenopausal with elevated homocysteine already documented
• Take anticonvulsants alongside Jardiance, since several antiepileptics (valproate, phenytoin, carbamazepine) independently deplete folate and may require higher supplementation doses per ACOG guidance on epilepsy in pregnancy

Monitoring: what to check and how often

No special monitoring is needed solely because of combining folate and empagliflozin. The monitoring schedule for Jardiance is driven by kidney function and glucose control.

Folate-specific monitoring is appropriate in these situations:

• Serum folate and red blood cell folate: baseline if MTHFR status is unknown and you are of reproductive age or have elevated cardiovascular risk
• Plasma homocysteine: if perimenopausal, post-menopausal with cardiovascular risk, or have confirmed MTHFR variant
• Serum B12: always check alongside folate; B12 deficiency can be masked by high-dose folate supplementation and metformin (commonly co-prescribed with empagliflozin) is a known cause of B12 malabsorption in up to 30% of long-term users
• Annual review of supplement regimen by your prescriber or registered dietitian